Active disease: clinically active disease of the bowel is defined clinically as at least mild activity using dedicated scoring indices or biochemically active disease as defined by a fecal calprotectin \> 60 μg/g
Patients must be eligible for risankizumab therapy
Minimum age of 18 years
Written informed consent
Clinical indication for an endoscopic procedure
Established IBD diagnosis
Patients must be on risankizumab therapy for at least 14 weeks
Minimum age of 18 years
Written informed consent
Clinical indication for an endoscopic procedure
You may not be if
A female study patient who is pregnant or provides breastfeeding
A female study patient of premenopausal age who does not use any reliable form of contraception at the time of risankizumab-800CW administration and the following 10 weeks
Medical or psychiatric conditions that compromise the patient's ability to give informed consent
Active extra gastrointestinal manifestations of Crohn's disease (e.g. uveitis or pyoderma gangrenosum at vital locations)
A female study patient who is pregnant or provides breastfeeding
A female study patient of premenopausal age who does not use any reliable form of contraception at the time of risankizumab-800CW administration and the following 10 weeks
Medical or psychiatric conditions that compromise the patient's ability to give informed consent
Active extra gastrointestinal manifestations of Crohn's disease (e.g. uveitis or pyoderma gangrenosum at vital locations)
Clareo Health | Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
